IMAX Presents at J.P. Morgan Conference; No New Disclosures, Thesis Unchanged

What happened

IMAX management presented at the J.P. Morgan 54th Annual Global Technology, Media and Communications Conference, but the transcript reveals no material new information beyond what was already disclosed in prior earnings and guidance. The presentation likely reiterated the record $1.28B 2025 global box office and the $1.4B 2026 target, themes already well embedded in the stock's valuation. The latest DeepValue master report rates IMAX a POTENTIAL SELL, arguing that at $35.13 the stock trades at ~48x trailing EPS and ~18x EV/EBITDA, pricing in a perfect execution of the 2026 slate and structurally higher margins. The report's base case implies $34 per share, with a bear case of $24 if box office or China performance disappoints. This conference provides no catalyst to alter the thesis that near-term risk-reward is unfavorable.

Implication

The conference presentation provided no new information that would alter the investment thesis. IMAX remains a POTENTIAL SELL given its elevated valuation (~48x trailing EPS, ~18x EV/EBITDA) and high dependence on a perfect execution of the 2026 slate. The master report's base case of $34 and bear case of $24 suggest limited upside and material downside risk. Investors should continue to monitor for signs of 2026 box office shortfalls or slower backlog conversion, which would justify a lower multiple. The stock should be avoided or trimmed above $42.

Thesis delta

No delta from this news. The thesis remains that at $35.13, IMAX prices in record 2025 and near-perfect 2026 slate execution, leaving limited upside and skew to downside. The conference presentation did not introduce any new risks or catalysts that change this assessment.